In vitro evaluation of dose-response curve for paclitaxel in breast cancer

Yoshimasu, Tatsuya; Oura, Shoji; Hirai, Ikuko; Tamaki, Takeshi; Kokawa, Yozo; Ota, Fuminori; Nakamura, Rie; Shimizu, Yukio; Kawago, Mitsumasa; Hirai, Yoshimitsu; Naito, Koma; Kiyoi, Megumi; Tanino, Hirokazu; Okamura, Yoshitaka; Furukawa, Tomoko

doi:10.2325/jbcs.14.401

Cited by 14 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug concentration-cell growth (that is, dose–response) curve is generally not linear, and ideally should be logistic. To evaluate drug sensitivity, the curve must show a logistic curve that is considered to be a pharmacological drug response [12,15]. We confirmed that hyperbolic dose–response curves are a sufficient indicator of drug resistance.…”

Section: Discussionsupporting

confidence: 60%

“…Rigid quantitation by conventional chemosensitivity assays has been quite challenging because the number of available tumor cells from solid tumors is extremely limited, which precludes the construction of drug dose–response curves from tumor cells [11,12]. The results from a limited number of data points may not be of sufficient quality for measuring the non-linear associations between drug dose and cell viability.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of chemosensitivity prediction using quantitative dose–response curve classification for highly advanced/relapsed gastric cancer

et al. 2013

View full text Add to dashboard Cite

BackgroundThe use of standard chemotherapy regimens has changed the application of chemosensitivity tests from all chemotherapy-eligible patients to those who have failed standard chemotherapy, which includes patients with highly advanced, relapsed, or chemoresistant tumors.MethodsWe evaluated a total of 43 advanced primary and relapsed gastric cancers for chemosensitivity based on drug dose response curves to improve the objectivity and quality of quantitative measurements. The dose response curves were classified based on seven expected patterns. Instead of a binary chemosensitivity evaluation, we ranked drug sensitivity according to curve shapes and comparison with the peak plasma concentration (ppc) of each drug.ResultsA total of 193 dose response curves were obtained. The overall informative rate was 67.4%, and 85.3% for cases that had a sufficient number of cells. Paclitaxel (PXL)and docetaxel tended to show a higher rank, while cisplatin (CIS) and 5-fluorouracil (5-FU) tended to show resistance, particularly among the 20 cases (46.5%) that had recurrent disease after receiving chemotherapy with CIS and S-1 (5-FU). As such, we speculate that the resistant pattern of the chemosensitivity test suggests that cells with acquired drug resistance were selected by chemotherapy. Indeed, we observed a change in the chemosensitivity pattern of a sample before and after chemotherapy in terms of PXL sensitivity, which was used after primary chemotherapy.ConclusionsThese results suggest that: (i) the dose–response pattern provides objective information for predicting chemosensitivity; and (ii) chemotherapy may select resistant cancer cell populations as a result of the therapy.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Introductionmentioning

confidence: 99%

Evaluation of chemosensitivity prediction using quantitative dose–response curve classification for highly advanced/relapsed gastric cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Good correlations between efficacy rate for an individual agent using HDRA in vitro assay and clinical response rate to each agent have been reported previously. These findings suggest that chemosensitivity determined from HDRA with MTT endpoint probably reflects chemosensitivity in vivo and would be suitable for clinical applications and are congruent with a number of prior studies reporting HDRA as a useful predictor for response to chemotherapy in various cancer (25)(26)(27)(28). These results show that HDRA allows conservation of the original phenotypic characteristics of tumor cells.…”

Section: Discussionsupporting

confidence: 76%

“…More recently, Furukawa et al (23) reported that HDRA with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) endpoint is clinically useful for chemosensitivity assay in the field of gastrointestinal surgery field. Although several studies have investigated the efficacy of HDRA with MTT endpoint in a variety of cancers (24)(25)(26)(27)(28), little work has been done to elucidate the clinical utility of HDRA with MTT endpoint for esophageal cancer (29).…”

Section: Introductionmentioning

confidence: 99%

Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer

Tanigawa¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Predicting response to chemotherapy would provide patients suffering from malignant tumor with not only more favorable outcomes, but also reduction of adverse events, and would enable chemotherapy tailored to individual patients. The purpose of this retrospective study was to evaluate the utility of histoculture drug response assay (HDRA) with the MTT endpoint. Subjects comprised 53 consecutive patients diagnosed with esophageal cancer, with 15 patients receiving preoperative chemoradiotherapy (CRT) followed by surgery (CRT group; n=15) and 38 patients undergoing surgery (surgery group; n=38), including 17 patients with histological lymph node metastasis who received postoperative chemotherapy. Tumor samples obtained from patients were used for HDRA with MTT endpoint and correlations of sensitivity from HDRA with MTT endpoint to clinical response to preoperative CRT, accuracy of in vitro sensitivity test, and clinical outcomes based on HDRA sensitivity were analyzed. HDRA was able to evaluate 379 of 424 assays (89.3%). In the CRT group, no significant correlation was confirmed between efficacy rate of 5-fluorouracil or cisplatin and histological findings in resected specimens after CRT. Efficacy rates of several anticancer agents using HDRA in the surgery group were observed in the range of 0.0-44.8%. On examination of clinical outcomes in the surgery group, in which patients with stage III received adjuvant chemotherapy, chemosensitivity-negative patients tended to display worse prognosis than chemosensitivity-positive patients. HDRA with MTT endpoint probably predicts the postoperative prognosis of patients with esophageal cancer.

show abstract

“…The inhibition rate at single concentrations is also not so varied. [15][16][17] For gefi tinib in our study, the 12 patients without dose-response curves probably did not have any sensitizing gene mutation in EGFR or had some gefi tinib-resistant molecular features.…”

Section: Discussionmentioning

confidence: 97%

Histoculture drug response assay for gefitinib in non-small-cell lung cancer

Yoshimasu

Ohta

Oura

et al. 2009

Gen Thorac Cardiovasc Surg

Self Cite

View full text Add to dashboard Cite

show abstract

In vitro evaluation of dose-response curve for paclitaxel in breast cancer

Abstract: An individual dose-response curve for paclitaxel in breast cancer can be obtained using the HDRA technique. Nuclear grade 3 tumors appeared to have more uniform chemosensitivity to paclitaxel compared with nuclear grade 1 and 2 tumors.

Cited by 14 publications

References 5 publications

Evaluation of chemosensitivity prediction using quantitative dose–response curve classification for highly advanced/relapsed gastric cancer

Evaluation of chemosensitivity prediction using quantitative dose–response curve classification for highly advanced/relapsed gastric cancer

Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer

Histoculture drug response assay for gefitinib in non-small-cell lung cancer

Contact Info

Product

Resources

About